Compare Nu Holdings Ltd (NU) vs 10X Genomics Inc (TXG) Price & Performance

NU Holdings Ltd. (NU) trades at $15.38, down 1.28% on the day, with a bullish technical signal from moving averages but a neutral reading from oscillators. The company reported strong revenue growth, with 2025 revenue reaching $10.63 billion and net income of $2.87 billion, though recent quarterly EPS results have been mixed. Analyst sentiment remains positive, with a consensus buy rating and a price target of $16.53.

The outlook for NU is supported by robust fundamentals and expanding customer base, but risks include credit exposure and acquisition speculation. The stock presents a growth opportunity if execution continues, yet investors must weigh high valuation multiples against potential macroeconomic headwinds in Latin American markets.

10x Genomics (TXG) trades at $77.28, up 1.55% on the day, with a bearish technical signal from moving averages. The company shows improving fundamentals with revenue of $642.82M in 2025 and a reduced net loss of -$43.54M, while recent news highlights strong demand for its Atera spatial biology platform and a patent victory. Positive earnings beats in recent quarters contrast with a high EV/EBITDA of 249.22, indicating significant growth expectations are priced in.

The outlook is mixed; analyst consensus is neutral with a $74.30 price target slightly below the current price, yet operational cash flow turned strongly positive in 2025. Key risks include persistent net losses, high valuation multiples, and execution on new product launches. The stock's near-term direction hinges on Atera's commercial success and achieving profitability.